Jean-Jacques Bienaimé

Jean-Jacques Bienaimé is recorded as Chairman at Keros Therapeutics, Inc. (KROS) since August 18, 2025 and Board Member at Keros Therapeutics, Inc. (KROS) since June 1, 2024. Keros Therapeutics, Inc. reported in an 8-K filed October 15, 2025 that Jean-Jacques Bienaimé was appointed Chair of the Nominating and Corporate Governance Committee, effective October 15, 2025. Keros Therapeutics, Inc. reported in an 8-K filed August 6, 2025 that Jean-Jacques Bienaimé was appointed Chair of the Board, effective August 18, 2025. Keros Therapeutics, Inc. reported in an 8-K filed June 17, 2024 that Jean-Jacques Bienaimé was appointed Lead Independent Director, effective July 1, 2024. Equibles holds 4 filed executive changes naming Jean-Jacques Bienaimé; each is listed under recent activity with its source filing. Keros Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Keros Therapeutics, Inc. includes Jasbir Seehra (CEO, Chairman and Board Member), Annita Tanini (Chief Accounting Officer), Alpna Seth (Board Member) and 3 others.